BusinessMelinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)By Nasdaq OMXJun 19, 2017, 8:30 PM UTC
BusinessMelinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical RadezolidBy Nasdaq OMXFeb 28, 2017, 1:02 PM UTC
BusinessMelinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical RadezolidBy Nasdaq OMXFeb 28, 2017, 1:02 PM UTC
BusinessCapsoVision, Inc. Announces FDA 510(k) Clearance for CapsoCam® PlusBy Nasdaq OMXNov 11, 2016, 8:44 PM UTC
